Cellular and molecular mechanisms of bleomycin-induced murine scleroderma: current update and future perspective
- PMID: 15679577
- DOI: 10.1111/j.0906-6705.2005.00280.x
Cellular and molecular mechanisms of bleomycin-induced murine scleroderma: current update and future perspective
Abstract
Scleroderma is a fibrotic condition characterized by immunologic abnormalities, vascular injury and increased accumulation of matrix proteins in the skin. Although the aetiology of scleroderma is not fully elucidated, a growing body of evidence suggests that extracellular matrix overproduction by activated fibroblasts results from complex interactions among endothelial cells, lymphocytes, macrophages and fibroblasts, via a number of mediators. Cytokines, chemokines and growth factors secreted by inflammatory cells and mesenchymal cells (fibroblasts and myofibroblasts) play an important role in the fibrotic process of scleroderma. Recently, we established a murine model of scleroderma by repeated local injections of bleomycin. Dermal sclerosis was induced in various mouse strains, although the intensity of dermal sclerosis varied among various strains. Histopathological and biochemical analysis demonstrated that this experimental murine scleroderma reflected a number of aspects of human scleroderma. Further investigation of the cellular and molecular mechanisms of inflammatory reaction, fibroblast activation and extracellular matrix deposition following dermal injury by bleomycin treatment will lead to the better understanding of the pathophysiology and the exploration of effective treatment against scleroderma. This review summarizes recent progress of the cellular and molecular events in the pathogenesis of bleomycin-induced scleroderma; moreover, further perspective by using this mouse model has been discussed.
Similar articles
-
The bleomycin-induced scleroderma model: what have we learned for scleroderma pathogenesis?Arch Dermatol Res. 2006 Feb;297(8):333-44. doi: 10.1007/s00403-005-0635-z. Epub 2006 Jan 10. Arch Dermatol Res. 2006. PMID: 16402183 Review.
-
Role of cytokines and proteases in murine scleroderma.J Med Dent Sci. 2008 Sep;55(3-4):215-25. J Med Dent Sci. 2008. PMID: 19697510 Review.
-
Scleroderma--pathophysiology.Eur J Dermatol. 2009 Jan-Feb;19(1):14-24. doi: 10.1684/ejd.2008.0570. Epub 2008 Dec 5. Eur J Dermatol. 2009. PMID: 19059831 Review.
-
Animal model of sclerotic skin. II. Bleomycin induced scleroderma in genetically mast cell deficient WBB6F1-W/W(V) mice.J Rheumatol. 1999 Dec;26(12):2628-34. J Rheumatol. 1999. PMID: 10606374
-
Animal model of systemic sclerosis.J Dermatol. 2010 Jan;37(1):26-41. doi: 10.1111/j.1346-8138.2009.00764.x. J Dermatol. 2010. PMID: 20175838 Review.
Cited by
-
Relevance of the stroma and epithelial-mesenchymal transition (EMT) for the rheumatic diseases.Arthritis Res Ther. 2006;8(3):210. doi: 10.1186/ar1963. Epub 2006 May 9. Arthritis Res Ther. 2006. PMID: 16689999 Free PMC article. Review.
-
Mouse Models of Skin Fibrosis.Methods Mol Biol. 2021;2299:371-383. doi: 10.1007/978-1-0716-1382-5_25. Methods Mol Biol. 2021. PMID: 34028755
-
Animal Models of Systemic Sclerosis: Using Nailfold Capillaroscopy as a Potential Tool to Evaluate Microcirculation and Microangiopathy: A Narrative Review.Life (Basel). 2022 May 8;12(5):703. doi: 10.3390/life12050703. Life (Basel). 2022. PMID: 35629370 Free PMC article. Review.
-
Identification of cadherin 11 as a mediator of dermal fibrosis and possible role in systemic sclerosis.Arthritis Rheumatol. 2014 Apr;66(4):1010-21. doi: 10.1002/art.38275. Arthritis Rheumatol. 2014. PMID: 24757152 Free PMC article.
-
Osteopontin in systemic sclerosis and its role in dermal fibrosis.J Invest Dermatol. 2012 Jun;132(6):1605-14. doi: 10.1038/jid.2012.32. Epub 2012 Mar 8. J Invest Dermatol. 2012. PMID: 22402440 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical